Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
A sharp sell-off grips both digital and traditional safe havens, with Bitcoin nearing a critical $80,000 level and gold suffering its worst drop in months, fueled by Fed uncertainty and tech sector anxieties.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
As the cryptocurrency market grapples with sustained selling pressure, a new analysis highlights significant vulnerabilities for two of the most recognizable digital assets, XRP and Dogecoin, projecting potential losses exceeding 50% in the coming year.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
Baidu's flagship AI assistant, Ernie, has surpassed 200 million monthly active users, a milestone reported by the Wall Street Journal. The growth underscores Baidu's deepening integration of AI across its ecosystem amid fierce competition with domestic tech rivals.
U.S. wheat futures declined across major exchanges on Friday, with Chicago, Kansas City, and Minneapolis contracts all trading lower. Despite the pullback, export sales data remains robust, running ahead of last year's pace.
Live cattle futures gained ground Friday, supported by steady cash trade, while feeder cattle contracts faced significant pressure. Market attention turns to the upcoming USDA Cattle Inventory report, expected to show a slight decline in total herd numbers.
Corn futures extended losses on Friday, pressured by a strengthening U.S. dollar and weaker crude oil prices. Despite robust export sales data running ahead of historical pace, front-month contracts fell 5 to 5.5 cents, pushing the national average cash price lower.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
While small-cap stocks can offer overlooked opportunities, their high-risk nature demands careful scrutiny. We examine three companies where valuation and business concerns suggest caution may be warranted.
While stocks priced between $10 and $50 can offer an appealing mix of accessibility and relative maturity, savvy investors know the sticker price is just the beginning. We examine one company in this range that appears poised for growth and two where the fundamentals warrant a closer, more cautious look.
While low-volatility stocks promise stability in turbulent markets, experts warn that their defensive appeal may mask underlying risks and missed opportunities for growth. We examine three such companies that investors might want to approach with caution.
Profitability alone doesn't guarantee a winning stock. We examine three firms—Chewy, RH, and Proto Labs—that are in the black but face significant headwinds that may limit their future returns, prompting investors to look elsewhere for growth.
Kratos Defense & Security Solutions (KTOS) has seen its stock price surge dramatically over the past six months, fueled by strong quarterly performance. However, a closer look at its cash flow, capital efficiency, and valuation suggests investors should proceed with caution. We analyze the risks and highlight a more compelling alternative in the security sector.
As the tech world's giants build their AI ambitions, chip designer Arm Holdings stands at the center. With its Q3 earnings report on the horizon, investors are weighing whether its foundational role justifies a premium valuation.
In remarks that now appear pointed, Fed Chair Jerome Powell robustly defended the central bank's personnel and economic frameworks just days before former Governor Kevin Warsh, a vocal critic, was nominated to potentially succeed him.
Altria Group (MO) posted stronger-than-expected Q4 revenue, driven by its core tobacco brands and oral nicotine products, but saw its shares fall as profit margins contracted sharply. The company is betting on a national rollout of its ON! Plus pouches and manufacturing upgrades to fuel its smoke-free future.